FDA agreed on trial design for Privosegtor in optic neuritis https://ymaho.com/fda-agreed-on-trial-design-for-privosegtor-in-optic-neuritis
FDA approved the design of registration trials for the neuroprotector Privosegtor for the treatment of optic neuritis. Learn how the drug can change neuro-ophthalmology and what prospects the SPA agreement opens.
FDA may approve ophthalmic bevacizumab Lytenava https://ymaho.com/fda-may-approve-ophthalmic-bevacizumab-lytenava
Analysis of the regulatory paradox: why the FDA rejected it three times, while Europe approved it. Learn how the Lytenava decision will change the $16 billion AMD market.
FDA approved the first ophthalmic bevacizumab LYTENAVA for the treatment of wet AMD https://ymaho.com/fda-approved-the-first-ophthalmic-bevacizumab-lytenava-for-the-treatment-of-wet-amd
FDA accepted Outlook Therapeutics' appeal and will approve LYTENAVA — a standardized bevacizumab for neovascular AMD. Analysis of consequences for the anti-VEGF market, pricing, and patients. Read more.
Targeted therapy for Usher syndrome 1B: new data on AAVB-081 https://ymaho.com/targeted-therapy-for-usher-syndrome-1b-new-data-on-aavb-081
Interim data from phase 1/2 gene therapy AAVB-081 for Usher syndrome 1B: safety, efficacy, and prognosis. Learn about the dual AAV vector and treatment prospects.